“Neutralizing interleukin-13 increases skin microbial diversity: results from a Phase 3, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis”, J of Skin, vol. 5, no. 6, p. s56, Nov. 2021, doi: 10.25251/skin.5.supp.56.